Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Aids in the muscle recovery process by reducing muscle tissue damage associated with a resistance training regimen
CJC-1295 Pregnancy & Lactation Safety: What the Evidence Actually Shows At a glance FDA pregnancy category / Not assigned (no human data exist) Human pregnancy trials / Zero completed or registered Human lactation trials / Zero completed or registered GH and IGF-1 elevation duration / Up to 8 days after a single DAC dose Recommended washout before conception / Minimum 30 days (clinical consensus) Breast milk excretion data / Unknown for CJC-1295 Regulatory status / Research peptide, 503A compounding only Animal reproductive toxicology / No published DART studies specific to CJC-1295 Half-life (DAC variant) / Approximately 5.8 to 8 days Half-life (no-DAC variant) / Approximately 30 minutes How CJC-1295 Works: Mechanism Relevant to Reproductive Safety CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, specifically the first 29 amino acids) with four amino acid substitutions that resist enzymatic degradation
Need for biomaterials to improve local therapeutic precision The convergence of hypoxia-driven radioresistance and immune suppression in cervical cancer creates a formidable therapeutic ceiling for conventional radiotherapy [67]
Ideal candidates include adults with BMI greater than 30 or BMI greater than 27 with weight-related health conditions, type 2 diabetes requiring glycemic control, or established cardiovascular disease
US$ 23.43
US$ 25.35
US$ 25.78
US$ 20.64
US$ 27.15
US$ 29.83
US$ 29.80
US$ 27.15
US$ 21.16
US$ 28.78
